Head and Neck Cancer
PV QA 2 - Poster Viewing Q&A 2
MO_28_2664 - Gemcitabine based induction chemotherapy may improve the survival of stage IVA nasopharyngeal carcinoma
Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3
Gemcitabine based induction chemotherapy may improve the survival of stage IVA nasopharyngeal carcinoma
J. Zong, J. Pan, C. Chen, Q. Guo, B. Wang, Y. Xu, and S. Lin; Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University, Fuzhou, China
Purpose/Objective(s): Patients with Stage IVA nasopharyngeal carcinoma (NPC) have the worst prognosis among locoregional disease. The purpose of this retrospective study was to evaluate the efficacy of gemcitabine based regimen versus paclitaxel based regimen when used as induction chemotherapy for stage IVA NPC.
Materials/Methods: A retrospective analysis of 145 patients of newly diagnosed stage IVA nasopharyngeal carcinoma (8th AJCC stage) between June, 2010 and December, 2012, was performed. All were treated with 2-3 cycles of induction chemotherapy followed by platinum-based concurrent chemoradiotherapy. The induction chemotherapy regimen was TP (paclitaxel + platinum) or GP (gemcitabine + platinum).
Results: The median follow-up was 57 months. Ninety-two patients (63.4%) underwent TP induction chemotherapy and 53 patients (36.6%) received GP induction chemotherapy. The clinical parameters were balanced between the two groups. Univariate and multivariate analysis showed that the regiment of induction chemotherapy was the main prognostic factor affecting overall survival (OS). The 5-year OS of GP group was higher than that of TP group (94.2% vs 75.4%, P = 0.007). The distant metastasis free survival of GP group was slightly higher than that of TP group (83.2% VS. 74.7%), however, the difference was not statistically significant (P = 0.425). The local recurrence free survival was similar between the two treatment groups (89.7% vs.89.5, P = 0.636).
Conclusion: GP regimen served as a first-line induction chemotherapy may improve the overall survival of NPC patients with stage IVA disease. It is worthy to be validated by further phase III clinical trials.
Author Disclosure: J. Zong: None. J. Pan: None. Y. Xu: None.